Thymidine analogue nucleoside reverse transcriptase inhibitors

1. Thymidine analogue nucleoside reverse transcriptase inhibitors are associated with hyperglycemia in humans (aHR 3.27, 95% CI 1.20–8.89).

   “prior thymidine analogue NRTI exposure (aHR 3.27, 95% CI 1.20-8.89)”

   HumansPrior exposure before dolutegravir-based antiretroviral therapyn = 8,856

   Incidence and Predictors of Hyperglycemia Among Adults Receiving Dolutegravir-Based Antiretroviral Therapy at Mbarara Regional Referral Hospital HIV Clinic, Uganda: A Retrospective Cohort Study

   HIV/AIDS (Auckland, N.Z.)·2 Oct 2026

More on Hyperglycemia